Indications: Solid tumors
PMC-309 is an engineered monoclonal antibody that targets the negative immune checkpoint human VISTA (V-domain Ig suppressor of T cell activation).
Mechanism of action / Target
PMC-309 binds to VISTA expressing cells such as myeloid-derived suppressor cells (MDSC) that inhibits VISTA-mediated T cell inactivation and proliferation.
The discovery of preclinical efficacy and mechanism of action is in progress using human VISTA-KI model in mice. The production of samples needed for the GLP-toxicity study is underway for the IND filing.